4/7/2008 From Bench to Bedside in One Year: Stem Cell Research Leads to Potential New Therapy for Rare Blood Disorder A unique partnership between industry and academia has led to human clinical trials of a new drug for a rare class of blood diseases
called myeloproliferative disorders (MPD), which are all driven by the same genetic mutation and can evolve into leuk... More...
Not exact matches
The team has shown that the microenvironment that controls hematopoietic stem cells can be targeted for the treatment of a set of
disorders called myeloproliferative neoplasias, the most prominent of which are chronic myelomonocytic leukemia (CMML), juvenile myelomonocytic leukemia (JMML), and atypical chronic myelogenous leukemia (CML).
You may also hear doctors
call them MPN or
myeloproliferative disorders (MPD).